






PHARMACEUTICAL 2016

Merrimack Pharmaceuticals INC Rank 263 of 295

The relative strengths and weaknesses of Merrimack Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merrimack Pharmaceuticals INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 5.0% points. The greatest weakness of Merrimack Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 150% points.

The company's Economic Capital Ratio, given in the ranking table, is 113%, being 151% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	201,394
Cost of Goods Sold	46
Intangible Assets	10,960
Liabilities, Current	103,746
Liabilities, Non-Current	257,655
Other Assets	611
Other Compr. Net Income	-96
Other Expenses	19,232
Other Liabilities	57,168
Other Net Income	1,016
Other Revenues	89,258
Property and Equipment	21,915
Research and Development	160,988
Selling, General and Administrative Expense	57,795

Output Variable	Value in 1000 USD
Assets	234,880
Liabilities	418,569
Expenses	238,061
Revenues	89,258
Stockholders Equity	-183,689
Net Income	-147,787
Comprehensive Net Income	-147,835
BaseVar	490,940
ECR before LimitedLiability	-168%
Economic Capital Ratio	113%